Skip to main content
Caplight Logo









Shanghai Juncell Therapeutics Co., Ltd.

Shanghai Juncell Therapeutics Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://juncell.com/

Last Round

Series B

Apr 1, 2024

Total Funding Raised

$100.12M

Company Overview

Shanghai Juncell Therapeutics Co., Ltd. is a biotechnology company that develops innovative tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tumor-infiltrating lymphocyteTIL therapycell therapysolid tumor treatmentimmunotherapycancer immunotherapygene-modified TILbiotechnologyclinical-stage biotechcell expansionnext-gen TILoncology R&Din vivo TILnon-viral gene modification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Juncell Therapeutics Co., Ltd. Comparables

Compare Shanghai Juncell Therapeutics Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Juncell Therapeutics Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeogenTC
88%
Grit Biotherapeutics
87%
Leman Biotech
84%

Shanghai Juncell Therapeutics Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 1, 2024
Series A ExtensionJan 15, 2022
Series AFeb 26, 2021
Pre SeedFeb 21, 2020

Shanghai Juncell Therapeutics Co., Ltd. Investors

Notable investors and investment history

Shanghai Juncell Therapeutics Co., Ltd. investors
InvestorRounds
Kaitai CapitalSeries A Extension, Series B, Series B Extension, Series A
YuanBio Venture CapitalSeries A Extension, Series B Extension
ALAN Asset ManagementSeries A Extension
Medfine CapitalSeries A
Oriza Seed Venture CapitalSeries A Extension, Series C, Series B Extension, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 15, 2022

    $24M round with participation from ALAN Asset Management and Kaitai Capital.

  • Feb 26, 2021

    $15.5M round led by Kaitai Capital.

Shanghai Juncell Therapeutics Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

Shanghai Juncell Therapeutics Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shanghai Juncell Therapeutics Co., Ltd.'s valuation, stock price, and market status.

Is Shanghai Juncell Therapeutics Co., Ltd. a public or private company?

Shanghai Juncell Therapeutics Co., Ltd. is a private company.

What is the current stock price of Shanghai Juncell Therapeutics Co., Ltd.?

Shanghai Juncell Therapeutics Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.

How much is Shanghai Juncell Therapeutics Co., Ltd. worth (valuation)?

Valuation information for Shanghai Juncell Therapeutics Co., Ltd. is not publicly available.

Can I buy Shanghai Juncell Therapeutics Co., Ltd. stock?

Shanghai Juncell Therapeutics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shanghai Juncell Therapeutics Co., Ltd.'s last funding round?

Shanghai Juncell Therapeutics Co., Ltd.'s most recent funding round was Series B on April 1, 2024.

Who are the main investors in Shanghai Juncell Therapeutics Co., Ltd.?

Key investors in Shanghai Juncell Therapeutics Co., Ltd. include Kaitai Capital, Oriza Seed Venture Capital.

Will Shanghai Juncell Therapeutics Co., Ltd. IPO soon?

No public IPO plans have been announced for Shanghai Juncell Therapeutics Co., Ltd..

How can I track Shanghai Juncell Therapeutics Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai Juncell Therapeutics Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range1
Year Founded2019
Last FundingApr 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?